Together with the finding that sera of all SPS patients inhibited GAD65 enzyme activity, while only 69% of sera of epileptic patients did, we conclude that GAD65Ab in epilepsy patients differ significantly from GAD65Ab in SPS patients and T1D patients. This evidence concerns the gene GAD2 and type 1 diabetes mellitus.